Kura Oncology Stock Price Prediction
| KURA Stock | USD 10.06 5.85 36.77% |
Oversold Vs Overbought
47
Oversold | Overbought |
EPS Estimate Next Quarter (0.65) | EPS Estimate Current Year (2.43) | EPS Estimate Next Year (2.72) | Wall Street Target Price 30.0769 | EPS Estimate Current Quarter (0.63) |
Using Kura Oncology hype-based prediction, you can estimate the value of Kura Oncology from the perspective of Kura Oncology response to recently generated media hype and the effects of current headlines on its competitors. We also analyze overall investor sentiment towards Kura Oncology using Kura Oncology's stock options and short interest. It helps to benchmark the overall future attitude of investors towards Kura using crowd psychology based on the activity and movement of Kura Oncology's stock price.
Kura Oncology Implied Volatility | 2.01 |
Kura Oncology's implied volatility exposes the market's sentiment of Kura Oncology stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Kura Oncology's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Kura Oncology stock will not fluctuate a lot when Kura Oncology's options are near their expiration.
The fear of missing out, i.e., FOMO, can cause potential investors in Kura Oncology to buy its stock at a price that has no basis in reality. In that case, they are not buying Kura because the equity is a good investment, but because they need to do something to avoid the feeling of missing out. On the other hand, investors will often sell stocks at prices well below their value during bear markets because they need to stop feeling the pain of losing money.
Kura Oncology after-hype prediction price | USD 10.2 |
There is no one specific way to measure market sentiment using hype analysis or a similar predictive technique. This prediction method should be used in combination with more fundamental and traditional techniques such as stock price forecasting, technical analysis, analysts consensus, earnings estimates, and various momentum models.
Kura |
Kura Oncology After-Hype Price Prediction Density Analysis
As far as predicting the price of Kura Oncology at your current risk attitude, this probability distribution graph shows the chance that the prediction will fall between or within a specific range. We use this chart to confirm that your returns on investing in Kura Oncology or, for that matter, your successful expectations of its future price, cannot be replicated consistently. Please note, a large amount of money has been lost over the years by many investors who confused the symmetrical distributions of Stock prices, such as prices of Kura Oncology, with the unreliable approximations that try to describe financial returns.
Next price density |
| Expected price to next headline |
Kura Oncology Estimiated After-Hype Price Volatility
In the context of predicting Kura Oncology's stock value on the day after the next significant headline, we show statistically significant boundaries of downside and upside scenarios based on Kura Oncology's historical news coverage. Kura Oncology's after-hype downside and upside margins for the prediction period are 5.08 and 15.32, respectively. We have considered Kura Oncology's daily market price in relation to the headlines to evaluate this method's predictive performance. Remember, however, there is no scientific proof or empirical evidence that news-based prediction models outperform traditional linear, nonlinear models or artificial intelligence models to provide accurate predictions consistently.
Current Value
Kura Oncology is somewhat reliable at this time. Analysis and calculation of next after-hype price of Kura Oncology is based on 3 months time horizon.
Kura Oncology Stock Price Prediction Analysis
Have you ever been surprised when a price of a Company such as Kura Oncology is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Kura Oncology backward and forwards among themselves. Have you ever observed a lot of a particular company's price movement is driven by press releases or news about the company that has nothing to do with actual earnings? Usually, hype to individual companies acts as price momentum. If not enough favorable publicity is forthcoming, the Stock price eventually runs out of speed. So, the rule of thumb here is that as long as this news hype has nothing to do with immediate earnings, you should pay more attention to it. If you see this tendency with Kura Oncology, there might be something going there, and it might present an excellent short sale opportunity.
| Expected Return | Period Volatility | Hype Elasticity | Related Elasticity | News Density | Related Density | Expected Hype |
0.92 | 5.12 | 0.14 | 0.21 | 7 Events / Month | 4 Events / Month | In about 7 days |
| Latest traded price | Expected after-news price | Potential return on next major news | Average after-hype volatility | ||
10.06 | 10.20 | 1.39 |
|
Kura Oncology Hype Timeline
Kura Oncology is now traded for 10.06. The entity has historical hype elasticity of 0.14, and average elasticity to hype of competition of 0.21. Kura is projected to increase in value after the next headline, with the price projected to jump to 10.2 or above. The average volatility of media hype impact on the company the price is over 100%. The price jump on the next news is projected to be 1.39%, whereas the daily expected return is now at -0.92%. The volatility of related hype on Kura Oncology is about 2242.34%, with the expected price after the next announcement by competition of 10.27. Net Loss for the year was (152.63 M) with profit before overhead, payroll, taxes, and interest of 0. Given the investment horizon of 90 days the next projected press release will be in about 7 days. Check out Kura Oncology Basic Forecasting Models to cross-verify your projections.Kura Oncology Related Hype Analysis
Having access to credible news sources related to Kura Oncology's direct competition is more important than ever and may enhance your ability to predict Kura Oncology's future price movements. Getting to know how Kura Oncology's peers react to changing market sentiment, related social signals, and mainstream news is a great way to find investing opportunities and time the market. The summary table below summarizes the essential lagging indicators that can help you analyze how Kura Oncology may potentially react to the hype associated with one of its peers.
| HypeElasticity | NewsDensity | SemiDeviation | InformationRatio | PotentialUpside | ValueAt Risk | MaximumDrawdown | |||
| ZVSA | ZyVersa Therapeutics | (0.01) | 5 per month | 0.00 | (0.14) | 9.17 | (10.36) | 78.93 | |
| SONN | Sonnet Biotherapeutics Holdings | 1.15 | 7 per month | 0.00 | (0.13) | 12.31 | (9.79) | 37.58 | |
| ZURA | Zura Bio Limited | 0.03 | 9 per month | 0.00 | (0.05) | 7.95 | (7.94) | 30.69 | |
| PHIO | Phio Pharmaceuticals Corp | 0.18 | 6 per month | 0.00 | (0.05) | 11.78 | (10.38) | 36.22 | |
| RNAZ | Transcode Therapeutics | 0.04 | 2 per month | 6.52 | 0.07 | 22.00 | (11.43) | 68.80 | |
| QNRX | Quoin Pharmaceuticals Ltd | (0.02) | 9 per month | 6.73 | 0.05 | 17.65 | (9.68) | 74.46 |
Kura Oncology Additional Predictive Modules
Most predictive techniques to examine Kura price help traders to determine how to time the market. We provide a combination of tools to recognize potential entry and exit points for Kura using various technical indicators. When you analyze Kura charts, please remember that the event formation may indicate an entry point for a short seller, and look at other indicators across different periods to confirm that a breakdown or reversion is likely to occur.| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
About Kura Oncology Predictive Indicators
The successful prediction of Kura Oncology stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as Kura Oncology, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of Kura Oncology based on analysis of Kura Oncology hews, social hype, general headline patterns, and widely used predictive technical indicators.
We also calculate exposure to Kura Oncology's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Kura Oncology's related companies.
Story Coverage note for Kura Oncology
The number of cover stories for Kura Oncology depends on current market conditions and Kura Oncology's risk-adjusted performance over time. The coverage that generates the most noise at a given time depends on the prevailing investment theme that Kura Oncology is classified under. However, while its typical story may have numerous social followers, the rapid visibility can also attract short-sellers, who usually are skeptical about Kura Oncology's long-term prospects. So, having above-average coverage will typically attract above-average short interest, leading to significant price volatility.
Contributor Headline
Latest Perspective From Macroaxis
Kura Oncology Short Properties
Kura Oncology's future price predictability will typically decrease when Kura Oncology's long traders begin to feel the short-sellers pressure to drive the price lower. The predictive aspect of Kura Oncology often depends not only on the future outlook of the potential Kura Oncology's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Kura Oncology's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 73.2 M | |
| Cash And Short Term Investments | 424 M |
Complementary Tools for Kura Stock analysis
When running Kura Oncology's price analysis, check to measure Kura Oncology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kura Oncology is operating at the current time. Most of Kura Oncology's value examination focuses on studying past and present price action to predict the probability of Kura Oncology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kura Oncology's price. Additionally, you may evaluate how the addition of Kura Oncology to your portfolios can decrease your overall portfolio volatility.
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |